New Thieme Research Awards: Call for Pacesetting Contributions to Drug Research

Authors

M. Wehling, R. Wenzel

Affiliations

1 Institute for Experimental and Clinical Pharmacology and Toxicology, Ruprecht-Karls-Universität Heidelberg, Mannheim, Germany
2 Georg Thieme Verlag KG, Stuttgart, Germany

Drug Research celebrates its 65th birthday this year demonstrating both the visionary power of the founder, [name], and the scientific success of myriads of authors, several editors and 2 publishers. No doubt, innovative pace in drug development and, thus, pharmacotherapy has steadily increased, and major breakthroughs – though not evenly distributed across all therapeutic areas – can be witnessed at a growing rate.

Only recently at the occasion of transition from Edition Cantor to Thieme as publisher, the development of the Journal was promoted by the complete transition to English as only language of the publication as well as by the accentuation of its translational orientation.

These changes were accompanied by the introduction of an electronic submission system resulting in facilitation of the world-wide access of authors to the Journal, and the acceleration of the peer-review system. In 2015, the mean time between submission and final editorial decision was only 37 days.

Though those changes were essential to secure the future of the Journal in an ever increasingly competitive environment of scientific journals, further means need to be instituted to strengthen its resilience. As a timely measure to promote the successful Journal, we proudly announce the endowment of the

Thieme Awards for the Most Innovative Original Paper

and for the

Best Critical Review.

i) Criteria of eligibility for the Most Innovative Original Paper are: relevant research purpose aiming at major unmet medical needs, scientific rigor, adequate design, execution and interpretation of investigations, novelty/innovation and translational orientation.

ii) Criteria of eligibility for the Best Critical Review are: relevant research topics aiming at major unmet medical needs, compliance with current standards of scientific reviews, in particular systematic reviews, added value against the background of related reviews elsewhere, comprehensiveness balanced against readability and volume.

All work must be original and must not have been published previously. Deadline: Please submit your contribution by June the 30th, 2017, to be eligible for these awards. Please state clearly that you wish your work to be considered for these awards when submitting. Also, clearly indicate who would be the primary recipient in case of multiple authors.

Only papers submitted through the online submission site will be considered: https://mc.manuscriptcentral.com/drugres

We hope that the scientific competition induced by the awards will not only increase the visibility of the Journal, but also inspire and support scientists to produce highly relevant and clinically oriented research in the realm of pharmacotherapy.

Prof. Martin Wehling,
Editor-in-Chief

Dr. Regina Wenzel,
Thieme Publishers